A DC-targeted nano-vaccine to overcome immune suppression and enhance the SoC efficacy for PDAC
Thursday, July 17, 2025
5:46 PM – 5:57 PM EDT
Introduction: Pancreatic ductal adenocarcinoma (PDAC) has a low survival rate due to its immunosuppressive tumor microenvironment (TME) and resistance to chemotherapy. To address this, we developed a dendritic cells (DCs)-targeted nanovaccine (NV) containing toll-like receptor (TLR) agonists and the PDAC tumor-associated antigens (TAA), CEACAM5 (CEA5) which is overexpressed in PDAC, to boost anti-cancer immunity. The CEA5 NV showed promising anti-tumor immune responses in patient-derived models and PDAC-bearing mice, both as a monotherapy and in combination with Gemcitabine and Nab-Paclitaxel (Gem/NabP).
Learning Objectives:
At the completion of this activity, participants will know
Understand the development of CEA5 NV to enhance anti-tumor immunity in pancreatic cancer treatment
Evaluate CEA5 NV's impact on TME, tumor growth, and survival in preclinical PDAC models.
Explore patient-derived 3D models to evaluate immune responses induced by the CEA5 nanovaccine
